Hörl W H, Schäfer R M, Heidland A
Eur J Clin Pharmacol. 1982;22(6):541-4. doi: 10.1007/BF00609628.
An inverse relationship between proteolytic activity in the presence of kallikrein 0.4 IU and urinary alpha1-antitrypsin concentration has been demonstrated. This protease inhibitor can directly inactivate kallikrein activity. The inhibition was abolished by removal of urinary alpha1-antitrypsin by trypsin-sepharose treatment. Inhibition could be reversed by addition of purified alpha1-antitrypsin. These effects could not be demonstrated with inter-alpha-trypsin inhibitor or alpha2-macroglobulin. The inhibitory effect of alpha1-antitrypsin on kallikrein activity should be taken into account in studies in which kallikrein activity is estimated.
已证实,在存在0.4 IU激肽释放酶的情况下,蛋白水解活性与尿α1-抗胰蛋白酶浓度呈负相关。这种蛋白酶抑制剂可直接使激肽释放酶活性失活。通过胰蛋白酶-琼脂糖处理去除尿α1-抗胰蛋白酶后,抑制作用消失。添加纯化的α1-抗胰蛋白酶可使抑制作用逆转。α1-抗胰蛋白酶抑制因子或α2-巨球蛋白则无此作用。在评估激肽释放酶活性的研究中,应考虑α1-抗胰蛋白酶对激肽释放酶活性的抑制作用。